A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases. We believe immunotherapies are one of the forward pillars of medicine, and our mission is to advance humanity by engineering immunotherapies that are safer, more effective and more broadly accessible. Although Chimeric Antigen Receptor T-cells (CAR-Ts) have shown benefits to date, they have primarily been constrained to existing biologic structures, which has limited their impact and opportunity. Our novel synthetic binding scaffold, the D-Domain, is designed to overcome the limitations of traditional CAR-Ts. Existing CAR-T therapy solutions, most of which use a biologic-based, single chain variable fragment (scFv) binding domain, tend to be difficult to manufacture, beneficial to a limited segment of patients, often result in high toxicity, and have narrow applicability in treatable indications.
| Metric | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | 0 | - | 108M | 110M |
| Net Income | -229M | -229M | -107M | -71M |
| EPS | $-4.07 | $-4.07 | $-2.00 | $-1.47 |
| Free Cash Flow | -213M | -213M | -97M | 186M |
| ROIC | -53.5% | -53.4% | -23.6% | -14.0% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.13 | 0.13 | 0.12 | 0.33 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -253M | -253M | -138M | -90M |
| Operating Margin | 0.0% | - | -127.5% | -81.5% |
| ROE | -56.9% | -53.4% | -23.6% | -14.6% |
| Shares Outstanding | 56M | 56M | 54M | 48M |
| Metric | 2023 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 110M | 108M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | 134M | 157M | 158M | 158M |
| SG&A | 66M | 88M | 118M | 118M |
| EBIT | -90M | -138M | -253M | -253M |
| Op. Margin | -81.5% | -127.5% | N/A | 0.0% |
| Net Income | -71M | -107M | -229M | -229M |
| Net Margin | -64.1% | -99.5% | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -14.0% | -23.6% | -53.4% | -53.5% |
| ROE | -14.6% | -23.6% | -53.4% | -56.9% |
| ROA | -8.6% | -15.1% | -34.8% | -37.9% |
| Cash Flow | ||||
| Op. Cash Flow | 208M | -83M | -210M | -210M |
| Free Cash Flow | 186M | -97M | -213M | -213M |
| Owner Earnings | 164M | -150M | -295M | -295M |
| CapEx | 21M | 13M | 2.3M | 2.3M |
| Maint. CapEx | 2.0M | 5.2M | 6.7M | 6.7M |
| Growth CapEx | 19M | 8.2M | 0 | 0 |
| D&A | 2.0M | 5.2M | 6.7M | 6.7M |
| CapEx/OCF | 10.3% | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 42M | 61M | 78M | 78M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -544M | -533M | -398M | -28M |
| Cash & Equiv. | 395M | 106M | 80M | 80M |
| Long-Term Debt | 21M | N/A | N/A | 52M |
| Debt/Equity | 0.33 | 0.12 | 0.13 | 0.13 |
| Interest Coverage | N/A | N/A | N/A | N/A |
| Equity | 485M | 455M | 402M | 402M |
| Total Assets | 825M | 711M | 604M | 604M |
| Total Liabilities | 340M | 257M | 202M | 202M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -389M | -497M | -726M | -726M |
| Working Capital | 598M | 474M | 358M | 358M |
| Current Assets | 716M | 599M | 462M | 462M |
| Current Liabilities | 118M | 125M | 104M | 104M |
| Per Share Data | ||||
| EPS | -1.47 | -2.00 | -4.07 | -4.07 |
| Owner EPS | 3.41 | -2.79 | -5.24 | -5.24 |
| Book Value | 10.09 | 8.47 | 7.15 | 7.15 |
| Cash Flow/Share | 4.32 | -1.56 | -3.74 | -3.95 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 48.1M | 53.7M | 56.2M | 56.2M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -28.2 |
| P/FCF | 14.7 | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | 5.6 | 9.3 | 9.2 | 16.1 |
| Price/Sales | 16.1 | 33.6 | N/A | N/A |
| FCF Yield | 6.8% | -2.3% | -5.8% | -3.3% |
| Market Cap | 2.7B | 4.2B | 3.7B | 6.5B |
| Avg. Price | 36.91 | 67.67 | 70.68 | 114.87 |
| Year-End Price | 56.88 | 79.08 | 65.71 | 114.87 |
Arcellx, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -5.7%.
Arcellx, Inc. (ACLX) has a 5-year average return on invested capital (ROIC) of -30.3%. This is below average and may indicate limited pricing power.
Arcellx, Inc. (ACLX) has a market capitalization of $6.5B. It is classified as a mid-cap stock.
Arcellx, Inc. (ACLX) does not currently pay a regular dividend.
Arcellx, Inc. (ACLX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Arcellx, Inc. (ACLX) generated $-213 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Arcellx, Inc. (ACLX) has a debt-to-equity ratio of 0.13. This indicates a conservatively financed balance sheet.
Arcellx, Inc. (ACLX) reported earnings per share (EPS) of $-4.07 in its most recent fiscal year.
Arcellx, Inc. (ACLX) has a return on equity (ROE) of -53.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Arcellx, Inc. (ACLX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Arcellx, Inc. (ACLX) has a book value per share of $7.15, based on its most recent annual SEC filing.